Inzidenz des erworbenen VWS bei 41 Patienten mit myeloproliferativen Erkrankungen

• Literatur

• 1 Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43 (01) 48-S58.
• 2 Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Exp Opin Invest Drugs 2000; 9 (02) 347-354.
• 3 Federici AB, Jacob H. et al. Acquired von Wille-brand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349.
• 4 Murugesan G, Aboudola S, Szpurka H. et al. Identification of the JAK2 V617F mutation in chronic myeloproliferaative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006; 125: 625-633.
• 5 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
• 6 Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F ea. Am Soc Hematol 2006; 240-245.
• 7 Budde U. et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1984; 68: 981-985.